Essity Explores Strategic Options for Consumer Tissue Unit
Event summary
- Essity's Board of Directors initiated a strategic review of its Consumer Tissue business area on May 6, 2026.
- The review evaluates potential separation or other ownership alternatives to maximize value creation.
- Consumer Tissue generated SEK 43.5 billion in net sales in 2025, representing 31% of Essity's total net sales.
- The business area operates 29 production facilities and employs approximately 13,000 people.
The big picture
Essity's strategic review of its Consumer Tissue business reflects a broader trend among conglomerates to streamline portfolios and unlock value in underperforming or non-core assets. The move comes as the consumer goods sector faces increasing pressure to adapt to shifting demand patterns and cost pressures. With the Consumer Tissue unit contributing significantly to Essity's revenue and profitability, the outcome of this review could have substantial implications for the company's strategic direction and financial performance.
What we're watching
- Separation Feasibility
- Whether Essity can execute a clean separation of its Consumer Tissue business while maintaining operational efficiency and market leadership.
- Value Realization
- The potential impact of the strategic review on Essity's stock price and investor perception of its long-term growth prospects.
- Market Dynamics
- How changes in the Consumer Tissue business could affect Essity's competitive position in Europe and Latin America.